Genfit S.A. (PA:GNFT) — Market Cap & Net Worth
Market Cap & Net Worth: Genfit S.A. (GNFT)
Genfit S.A. (PA:GNFT) has a market capitalization of $424.82 Million (€363.37 Million) as of June 17, 2026. Listed on the PA stock exchange, this France-based company holds position #13283 globally and #197 in its home market, demonstrating a 8.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genfit S.A.'s stock price €9.48 by its total outstanding shares 50096219 (50.10 Million). Review total liabilities of Genfit S.A. to assess the company's total debt and financial obligations.
Genfit S.A. Market Cap History: 2015 to 2026
Genfit S.A.'s market capitalization history from 2015 to 2026. Data shows change from $1.85 Billion to $555.22 Million (-11.77% CAGR).
Index Memberships
Genfit S.A. is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$235.19 Billion | 0.18% | #70 of 119 |
|
CAC Small90
CACS
|
$36.74 Billion | 1.16% | #21 of 64 |
|
CAC All-Tradable
CACT
|
$2.89 Trillion | 0.01% | #130 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.89 Trillion | 0.01% | #130 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.89 Trillion | 0.01% | #130 of 179 |
|
CAC PME
CAPME
|
$40.07 Billion | 1.06% | #14 of 34 |
|
CAC Health Care
FRHC
|
$260.58 Billion | 0.16% | #18 of 36 |
Weight: Genfit S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genfit S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genfit S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.71x
Genfit S.A.'s market cap is 4.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.23 Billion | $284.00K | -$33.67 Million | 4332.78x | N/A |
| 2017 | $1.40 Billion | $118.00K | -$58.60 Million | 11872.38x | N/A |
| 2018 | $1.02 Billion | $69.00K | -$79.52 Million | 14726.82x | N/A |
| 2019 | $1.03 Billion | $30.84 Million | -$65.14 Million | 33.52x | N/A |
| 2020 | $233.80 Million | $765.00K | -$101.22 Million | 305.62x | N/A |
| 2021 | $252.78 Million | $80.07 Million | $67.26 Million | 3.16x | 3.76x |
| 2022 | $232.40 Million | $20.20 Million | -$23.72 Million | 11.51x | N/A |
| 2023 | $207.33 Million | $28.57 Million | -$28.89 Million | 7.26x | N/A |
| 2024 | $207.04 Million | $67.00 Million | $1.51 Million | 3.09x | 137.38x |
| 2025 | $308.36 Million | $65.43 Million | -$85.97 Million | 4.71x | N/A |
Competitor Companies of GNFT by Market Capitalization
Companies near Genfit S.A. in the global market cap rankings as of June 17, 2026.
Key companies related to Genfit S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Genfit S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Genfit S.A.'s market cap moved from $1.85 Billion to $ 555.22 Million, with a yearly change of -11.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €555.22 Million | +80.06% |
| 2025 | €308.36 Million | +48.94% |
| 2024 | €207.04 Million | -0.14% |
| 2023 | €207.33 Million | -10.79% |
| 2022 | €232.40 Million | -8.06% |
| 2021 | €252.78 Million | +8.12% |
| 2020 | €233.80 Million | -77.38% |
| 2019 | €1.03 Billion | +1.73% |
| 2018 | €1.02 Billion | -27.47% |
| 2017 | €1.40 Billion | +13.85% |
| 2016 | €1.23 Billion | -33.46% |
| 2015 | €1.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Genfit S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $424.82 Million USD |
| MoneyControl | $424.82 Million USD |
| MarketWatch | $424.82 Million USD |
| marketcap.company | $424.82 Million USD |
| Reuters | $424.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more